~6 spots leftby Feb 2026

A Study of Imlunestrant (LY3484356) in Healthy Women

Palo Alto (17 mi)
Age: 18+
Sex: Female
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Eli Lilly and Company
No Placebo Group

Trial Summary

What is the purpose of this trial?The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.

Eligibility Criteria

Treatment Details

1Treatment groups
Experimental Treatment
Group I: Midazolam + ImlunestrantExperimental Treatment2 Interventions
Midazolam administered orally alone on day 1 followed by imlunestrant administered orally alone on days 3 to 8. On day 9, midazolam is administered orally in combination with imlunestrant orally.

Find a clinic near you

Research locations nearbySelect from list below to view details:
Labcorp Clinical Research Unit Inc.Dallas, TX
Labcorp Clinical Research Unit Inc,Daytona Beach, FL
LabCorp CRU, Inc.Dallas, TX
LabCorp CRU, Inc.Daytona Beach, FL
Loading ...

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

References